{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:21:50Z","timestamp":1772781710441,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T00:00:00Z","timestamp":1372809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2334-13-304","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T02:29:08Z","timestamp":1372818548000},"source":"Crossref","is-referenced-by-count":9,"title":["The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia"],"prefix":"10.1186","volume":"13","author":[{"given":"Anneli","family":"Uusk\u00fcla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"M\u00fc\u00fcrsepp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mait","family":"Raag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikk","family":"J\u00fcrisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Pillsbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,3]]},"reference":[{"issue":"5","key":"2509_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2165\/11599470-000000000-00000","volume":"72","author":"K Seto","year":"2012","unstructured":"Seto K, Marra F, Raymakers A, Marra CA: The cost effectiveness of human papillomavirus vaccines: a systematic review. Drugs. 2012, 72 (5): 715-743. 10.2165\/11599470-000000000-00000.","journal-title":"Drugs"},{"issue":"6","key":"2509_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/1403494810377684","volume":"38","author":"G Vanagas","year":"2010","unstructured":"Vanagas G, Padaiga Z, Kurtinaitis J, Logminiene Z: Cost-effectiveness of 12-and 15-year-old girls' human papillomavirus 16\/18 population-based vaccination programmes in Lithuania. Scand J Public Health. 2010, 38 (6): 639-647. 10.1177\/1403494810377684.","journal-title":"Scand J Public Health"},{"issue":"1","key":"2509_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3111\/13696990903546013","volume":"13","author":"EJ Dasbach","year":"2010","unstructured":"Dasbach EJ, Nagy L, Brandtm\u00fcller A, Elbasha EH: The cost effectiveness of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in Hungary. J Med Econ. 2010, 13 (1): 110-118. 10.3111\/13696990903546013.","journal-title":"J Med Econ"},{"issue":"4","key":"2509_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/eurpub\/ckp208","volume":"20","author":"M Obradovic","year":"2010","unstructured":"Obradovic M, Mrhar A, Kos M: Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health. 2010, 20 (4): 415-421. 10.1093\/eurpub\/ckp208.","journal-title":"Eur J Public Health"},{"key":"2509_CR5","first-page":"43","volume":"2","author":"MP Kostinov","year":"2012","unstructured":"Kostinov MP, Zverev VV: [Economic effectiveness of vaccination against papilloma virus in the Russian Federation]. Zh Mikrobiol Epidemiol Immunobiol. 2012, 2: 43-50. [Article in Russian]","journal-title":"Zh Mikrobiol Epidemiol Immunobiol"},{"key":"2509_CR6","volume-title":"GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010, Lyon, France: International Agency for Research on Cancer, http:\/\/globocan.iarc.fr ,"},{"key":"2509_CR7","volume-title":"Haiguste ennetamise projektide 2010. aasta tulemused (The results of the disease prevention pojrects in 2010","author":"Eesti haigekassa 2010 (HIF 2010)","year":"2010","unstructured":"Eesti haigekassa 2010 (HIF 2010): Haiguste ennetamise projektide 2010. aasta tulemused (The results of the disease prevention pojrects in 2010. 2010, http:\/\/www.haigekassa.ee\/uploads\/userfiles\/2010_HE_tulemused.pdf ,"},{"issue":"4","key":"2509_CR8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/030089161009600403","volume":"96","author":"P Veerus","year":"2010","unstructured":"Veerus P, Arbyn M, Amati C, Paolo B, EUROCHIP Working Group: Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Tumori. 2010, 96 (4): 524-528.","journal-title":"Tumori"},{"key":"2509_CR9","unstructured":"State agency of medicines, Estonia: Marketing authorisation of medicinal products. http:\/\/193.40.10.165\/register\/register.php?keel=eng&inim_vet=inim ,"},{"key":"2509_CR10","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","volume":"28","author":"EH Elbasha","year":"2010","unstructured":"Elbasha EH, Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010, 28: 6858-6867. 10.1016\/j.vaccine.2010.08.030.","journal-title":"Vaccine"},{"key":"2509_CR11","volume-title":"Data on insured by EHIF in 2008","author":"Estonian health insurance fund","year":"2008","unstructured":"Estonian health insurance fund: Data on insured by EHIF in 2008. 2008, http:\/\/www.haigekassa.ee\/uploads\/userfiles\/V15_4_kv__2008_kindlustatute_statistika_prioriteet_gruppides.xls ,"},{"key":"2509_CR12","unstructured":"Statistics Estonia: Population of Estonia. http:\/\/www.stat.ee ,"},{"key":"2509_CR13","volume-title":"Estonian Health Interview Survey 2006 (EHIS 2006)","author":"National institutes of health","year":"2006","unstructured":"National institutes of health: Estonian Health Interview Survey 2006 (EHIS 2006). 2006, http:\/\/www2.tai.ee\/ETeU\/met_51.pdf ,"},{"key":"2509_CR14","volume-title":"Public-use data (1973\u20132002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch","author":"Surveillance, Epidemiology, and End Results (SEER) program","year":"2005","unstructured":"Surveillance, Epidemiology, and End Results (SEER) program: Public-use data (1973\u20132002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. 2005, http:\/\/www.seer.cancer.gov ,"},{"key":"2509_CR15","volume-title":"Inimese papilloomiviiruse Vastaste vaktsiinide kulut\u00f5husus Eestis","author":"K Liiv","year":"2011","unstructured":"Liiv K, Lutsar K, Palm E, Uusk\u00fcla A, Kiivet RA: Inimese papilloomiviiruse Vastaste vaktsiinide kulut\u00f5husus Eestis. 2011, Tartu \u00dclikooli tervishoiu instituut 2011. (Cost effectiveness of human papillomavirus vaccines in Estonia. Department of public health, University of Tartu, 2011), http:\/\/www.rahvatervis.ut.ee\/bitstream\/1\/4921\/1\/Lutsar2011.pdf ,"},{"key":"2509_CR16","volume-title":"National immunization program implementation","author":"Estonian Health Board","year":"2010","unstructured":"Estonian Health Board: National immunization program implementation. 2010, http:\/\/www.terviseamet.ee\/nakkushaigused\/vaktsineerimine\/riiklik-immuniseerimiskava-ja-selle-taitmine.html ,"},{"key":"2509_CR17","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine: report of the panel on cost-effectiveness in health and medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR, Siegel JE, Russell LB, Mce W: Cost-effectiveness in health and medicine: report of the panel on cost-effectiveness in health and medicine. 1996, New York, NY: Oxford University Press"},{"key":"2509_CR18","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","author":"TTT Edejer","year":"2003","unstructured":"Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB: Making choices in health: WHO guide to cost-effectiveness analysis. 2003, Geneva: World Health Organisation"},{"issue":"12","key":"2509_CR19","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","volume":"22","author":"M Arbyn","year":"2011","unstructured":"Arbyn M, Castellsagu\u00e9 X, de Sanjos\u00e9 S, Bruni L, Saraiya M, Bray F, Ferlay J: Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011, 22 (12): 2675-2686. 10.1093\/annonc\/mdr015.","journal-title":"Ann Oncol"},{"key":"2509_CR20","volume-title":"GDP and main components - Current prices","author":"Eurostat","year":"2012","unstructured":"Eurostat: GDP and main components - Current prices. 2012, http:\/\/appsso.eurostat.ec.europa.eu\/nui\/show.do?dataset=nama_gdp_c&lang=en ,"},{"key":"2509_CR21","volume-title":"CHOosing Interventions that are Cost Effective (WHO-CHOICE)","author":"World health organization","year":"2009","unstructured":"World health organization: CHOosing Interventions that are Cost Effective (WHO-CHOICE). 2009, http:\/\/www.who.int\/choice\/book\/en\/index.html ,"},{"issue":"17","key":"2509_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","volume":"365","author":"JM Palefsky","year":"2011","unstructured":"Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011, 365 (17): 1576-1585. 10.1056\/NEJMoa1010971.","journal-title":"N Engl J Med"},{"issue":"10","key":"2509_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","volume":"2","author":"SK Kjaer","year":"2009","unstructured":"Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009, 2 (10): 868-878. 10.1158\/1940-6207.CAPR-09-0031.","journal-title":"Cancer Prev Res (Phila)"},{"key":"2509_CR24","first-page":"1915","volume":"19","author":"II Study Future Group","year":"2007","unstructured":"II Study Future Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007, 19: 1915-1927.","journal-title":"N Engl J Med"},{"key":"2509_CR25","first-page":"10","volume-title":"IARC Handbooks of Cancer Prevention: Cervix Cancer Screening","author":"International Agency for Research on Cancer","year":"2005","unstructured":"International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention: Cervix Cancer Screening. 2005, Lyon: IARC Press, 10-"},{"issue":"17","key":"2509_CR26","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/S0959-8049(00)00330-0","volume":"36","author":"M van Ballegooijen","year":"2000","unstructured":"van Ballegooijen M, van den Akker-van ME, Patnick J, Lynge E, Arbyn M, Anttila A: Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer. 2000, 36 (17): 2177-2188. 10.1016\/S0959-8049(00)00330-0.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2509_CR27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.bjc.6602069","volume":"91","author":"A Anttila","year":"2004","unstructured":"Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M: Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer. 2004, 91 (5): 935-941.","journal-title":"Br J Cancer"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-304\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T18:04:56Z","timestamp":1715623496000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2509"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-304","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,3]]},"article-number":"304"}}